Yan, XiangZhang, MingxinChen, XiaoxiangWei, WangYang, RongYang, YangGan, WeidongGuo, HongqianWang, YangShi, Guo-Ping2015-07-132015Yan, Xiang, Mingxin Zhang, Xiaoxiang Chen, Wang Wei, Rong Yang, Yang Yang, Weidong Gan, Hongqian Guo, Yang Wang, and Guo-Ping Shi. 2015. “Image-guided percutaneous renal cryoablation for stage 1 renal cell carcinoma with high surgical risk.” World Journal of Surgical Oncology 13 (1): 200. doi:10.1186/s12957-015-0610-x. http://dx.doi.org/10.1186/s12957-015-0610-x.1477-7819http://nrs.harvard.edu/urn-3:HUL.InstRepos:17295646Background: This study was undertaken to evaluate the feasibility, safety, and therapeutic effects of percutaneous renal cryoablation under local anesthesia with conscious sedation for patients who have unresectable stage 1 (T1NoMo) renal cell carcinoma (RCC) in high surgical risk. Methods: Eighteen patients who were not candidates for surgery underwent primary cryosurgery guided by gray-scale ultrasound. Contrast-enhanced ultrasonography (CEUS) and contrast-enhanced computed tomography (CT) were performed to evaluate treatment at completion. Results: The mean follow-up period was 26.8 months (range, 12–56 months). All tumors were biopsied before cryosurgery. Seventeen tumors remained free of enhancement during follow-up period. No major complications associated with cryoablation procedures were found though two instances of subcapsular hematomas, one of retroperitoneal errhysis and one of nausea, were seen after cryoablation. One patient had a local recurrence of tumor and received additional cryoablation. Local tumor control rate was 100 % of T1NoMo tumors including the recurrence case who underwent additional cryoablation. Conclusions: Percutaneous cryoablation can be recommended as a feasible, safe, and promising therapy for the treatment of renal tumor, especially those unresectable stage 1 RCC, with a low risk of complications.en-USCryoablationRenal cell carcinomaLocal anesthesiaJournal Article2015-07-1310.1186/s12957-015-0610-x